Its LifeSciences and Applied Markets segment recorded $515 million in revenues in thequarter, down 4 percent from $539 million a year ago. Its Diagnostics andGenomics revenues were up 4 percent to $178 million from $172 million in Q4 FY2014. Revenues from the company’s CrossLab group were up 3 percent to $342million from $332 million in the year-ago period.
Agilent'sprofit for Q4 FY 2015 rose to $140 million, or $.42 per share, from $23million, or $.07 per share, a year ago. On an adjusted basis, its EPS was $.50,beating the consensus Wall Street estimate of $.47.
Agilenthad intangible amortization of $37 million, transformation costs of $15million, acquisition and integration costs of $7 million, asset impairments of$3 million, and a tax benefit of $39 million. The company had R&D costs of$82 million in the quarter, down 15 percent from $97 million a year ago. ItsSG&A spending fell 5 percent to $297 million from $312 million.